Latest
BioSpectrum Asia Market update
Fangzhou launches Novo Nordisk’s once-weekly basal insulin/GLP-1 therapy in China
Fangzhou Inc. SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, further expanding its collaboration with global healthcare company Novo Nordisk to improve access to …